Clinical Trials Directory

Trials / Conditions / Prader-Willi Syndrome

Prader-Willi Syndrome

133 registered clinical trials studyying Prader-Willi Syndrome22 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study of CSTI-500 in Patients With Prader-Willi Syndrome
NCT07348601
ConSynance TherapeuticsPhase 2
Not Yet RecruitingA 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prade
NCT07266324
Bright Minds Biosciences Pty LtdPhase 2
Enrolling By InvitationObservational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
NCT07450664
Soleno Therapeutics, Inc.
Enrolling By InvitationA Study of Pitolisant in Participants With Prader-Willi Syndrome
NCT07219485
Harmony Biosciences Management, Inc.Phase 3
Not Yet RecruitingBrain Olfactory Pathways in Prader-Willi Syndrome
NCT07006207
University Hospital, ToulouseN/A
RecruitingTirzepatide in PWS, HO and GNSO
NCT06901245
Grace KimPhase 4
RecruitingAutistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
NCT06877715
University Hospital, Toulouse
Active Not RecruitingA Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597
Rhythm Pharmaceuticals, Inc.Phase 2
CompletedFunctional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact
NCT06900335
Corporacion Parc Tauli
RecruitingPhysical Activity and Community EmPOWERment Project
NCT06740162
University of North Carolina, Chapel HillN/A
SuspendedARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
NCT06828861
Aardvark Therapeutics, Inc.Phase 3
SuspendedThe Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
NCT07197034
Aardvark Therapeutics, Inc.Phase 3
RecruitingInstitutional Registry of Rare Diseases
NCT06573723
Hospital Italiano de Buenos Aires
RecruitingA Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464
Harmony Biosciences Management, Inc.Phase 3
RecruitingA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116
Rhythm Pharmaceuticals, Inc.Phase 1 / Phase 2
UnknownAdolescent Projections During Transition in Prader-Willi Syndrome
NCT06279052
University Hospital, ToulouseN/A
CompletedRespiratory Restriction in Prader-Willi Syndrome
NCT06851351
Istituto Auxologico Italiano
Active Not RecruitingA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
NCT06144645
Foundation for Prader-Willi ResearchPhase 3
RecruitingEffects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Wi
NCT06720571
University of BordeauxN/A
RecruitingImpact of Bright Light Therapy on Prader-Willi Syndrome
NCT05939453
Maimonides Medical CenterN/A
WithdrawnAn Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
NCT05879614
Neuren Pharmaceuticals LimitedPhase 2
RecruitingCerebellar TMS and Satiety in Prader-Willi Syndrome
NCT05938543
Brigham and Women's HospitalN/A
WithdrawnMitochondrial Complex I Dysfunction in PWS
NCT03831425
The Hospital for Sick ChildrenPhase 2
CompletedEvaluation of the Psychological Profile of Adult Patients With Prader-Willi Syndrome
NCT06295315
Istituto Auxologico Italiano
CompletedDevelopment of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome
NCT05783791
University of Wisconsin, Madison
RecruitingThe Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
NCT05791604
Children's Hospital of Fudan UniversityN/A
Not Yet RecruitingGrowth Hormone Study in Adults With Prader-Willi Syndrome
NCT04484051
Erasmus Medical Center
Active Not RecruitingOpen-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
NCT05701774
Soleno Therapeutics, Inc.Phase 3
CompletedUnderstanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
NCT05541003
Rutgers, The State University of New JerseyPhase 2
WithdrawnA Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
NCT05387798
Radius Pharmaceuticals, Inc.Phase 3
CompletedA Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
NCT05504395
ConSynance TherapeuticsPhase 1
CompletedUltrasound to Assess Sarcopenia in Prader Willi Syndrome
NCT06448871
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
CompletedStudy to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
NCT05322096
Gedeon Richter Plc.Phase 2
CompletedA Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
NCT05153434
Aardvark Therapeutics, Inc.Phase 2
Active Not RecruitingBiological Age Assessment in Adults With Prader-Willi Syndrome (ETABIOLPWS)
NCT05778032
Istituto Auxologico Italiano
CompletedCharacterization of Serum Proteome in Subjects With Prader Willi Syndrome (PROTEOMARKER)
NCT05761184
Istituto Auxologico Italiano
TerminatedA Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndr
NCT05098509
Radius Pharmaceuticals, Inc.Phase 2 / Phase 3
CompletedEffect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome
NCT05298085
University Hospital, ToulousePhase 2 / Phase 3
WithdrawnStudy of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
NCT05198362
SanionaPhase 2
CompletedImproving Care of Prader-Willi Syndrome : Evaluation of a New Care Program Combining Adapted Physical Activity
NCT05249998
Assistance Publique - Hôpitaux de ParisN/A
RecruitingLong-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical
NCT05032326
University Hospital, ToulousePhase 3
UnknownGhrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overw
NCT04768803
University Hospital, Toulouse
CompletedStudy of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
NCT04697381
PfizerPhase 3
CompletedProbiotic Treatment for Prader-Willi Syndrome
NCT04685057
Fundació Sant Joan de DéuN/A
CompletedGuanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader
NCT05657860
Maimonides Medical CenterPhase 4
Active Not RecruitingA Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Foll
NCT04257929
Harmony Biosciences Management, Inc.Phase 2
CompletedCBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
NCT03848481
Montefiore Medical CenterPhase 2
CompletedStudy of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation
NCT04526379
University Hospital, ToulouseN/A
WithdrawntVNS in Children With Prader-Willi Syndrome
NCT04396470
Stanford UniversityPhase 1 / Phase 2
CompletedAssessment of CAI in Adults With PWS.
NCT04700644
Medical University of Warsaw
CompletedOxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome
NCT04283578
University Hospital, ToulousePhase 3
WithdrawnDose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior
NCT04066088
NYU Langone HealthPhase 4
WithdrawnAn Open-Label Study of DCCR Tablet in Patients With PWS
NCT04086810
Soleno Therapeutics, Inc.Phase 3
CompletedPWS Outcomes Assessment Study
NCT04102839
Soleno Therapeutics, Inc.
CompletedFiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome
NCT04150991
University of AlbertaN/A
UnknownStress and Brain Response Using MEG in PWS
NCT04032639
The Hospital for Sick Children
TerminatedHome-based SSP on Individuals With PWS
NCT03871751
Indiana UniversityN/A
TerminatedEffects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome
NCT03790865
Millendo Therapeutics SASPhase 2 / Phase 3
Enrolling By InvitationParent and Infant Inter(X)Action Intervention (PIXI)
NCT03836300
RTI InternationalN/A
CompletedPhase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
NCT03649477
Levo Therapeutics, Inc.Phase 3
Enrolling By InvitationEarly Check: Expanded Screening in Newborns
NCT03655223
RTI International
RecruitingGROWing Up With Rare GENEtic Syndromes
NCT04463316
dr. Laura C. G. de Graaff-Herder
CompletedOpen-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal
NCT03714373
Soleno Therapeutics, Inc.Phase 3
CompletedNatural History Study of Serious Medical Events in PWS
NCT03718416
Foundation for Prader-Willi Research
TerminatedA Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Particip
NCT03458416
Radius Pharmaceuticals, Inc.Phase 2
TerminatedCannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
NCT02844933
Radius Pharmaceuticals, Inc.Phase 2
CompletedA Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
NCT03440814
Soleno Therapeutics, Inc.Phase 3
UnknownA Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Pra
NCT03554031
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
CompletedIntranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT03197662
Eric HollanderPhase 2
CompletedA Study of GLWL-01 in Patients With Prader-Willi Syndrome
NCT03274856
GLWL Research Inc.Phase 2
CompletedTargeting the Gut Microbiome for Prader-Willi Syndrome Treatment
NCT03548480
Fundació Sant Joan de DéuN/A
TerminatedOptimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory
NCT03101826
Indiana UniversityN/A
CompletedIntranasal Oxytocin for Infants With Prader-Willi Syndrome
NCT03245762
University of FloridaPhase 1 / Phase 2
UnknownA 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choli
NCT02893618
Essentialis, Inc.Phase 2
CompletedGH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Co
NCT03616509
Corporacion Parc TauliPhase 4
UnknownEffects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome
NCT03324906
Federal University of São PauloN/A
RecruitingIDMet (RaDiCo Cohort) (RaDiCo-IDMet)
NCT05945576
Institut National de la Santé Et de la Recherche Médicale, France
CompletedFollow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.
NCT03081832
University Hospital, ToulouseN/A
CompletedOxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years
NCT03114371
University Hospital, ToulouseN/A
CompletedOxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome
NCT03031626
The Hospital for Sick ChildrenPhase 4
UnknownTherapeutic Effects of Hippotherapy in Children With Prader-Willi Syndrome
NCT03858023
Samsung Medical CenterN/A
UnknownPost Exercise Irisin Levels in PWS Patients
NCT02728544
Shaare Zedek Medical CenterN/A
CompletedEffects of Progressive Elastic Band Resistance Training
NCT03565081
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationN/A
CompletedProof of Concept Study of Vagus Nerve Stimulation
NCT03689621
Jessica Beresford-WebbN/A
CompletedOxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
NCT02629991
Montefiore Medical CenterPhase 2
CompletedSNP-based Microdeletion and Aneuploidy RegisTry (SMART)
NCT02381457
Natera, Inc.
CompletedPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Will
NCT02311673
Rhythm Pharmaceuticals, Inc.Phase 2
CompletedOxytocin Trial in Prader-Willi Syndrome
NCT02013258
University of FloridaPhase 1
UnknownDeep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome
NCT02297022
University of Sao Paulo General HospitalPhase 1
Active Not RecruitingPREPL in Health and Disease
NCT02263781
Universitaire Ziekenhuizen KU LeuvenN/A
TerminatedDouble-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syn
NCT02179151
Zafgen, Inc.Phase 3
CompletedGrowth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
NCT02205450
Corporacion Parc Tauli
CompletedEffects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome
NCT02804373
University Hospital, ToulousePhase 2 / Phase 3
CompletedStudy to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome
NCT02204163
LG Life SciencesPhase 3
CompletedPrader-Willi Syndrome Macronutrient Study
NCT02011360
Duke UniversityN/A
CompletedClinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
NCT02034071
Essentialis, Inc.Phase 1 / Phase 2
CompletedDiagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome
NCT02368379
Nationwide Children's HospitalN/A
CompletedHypoglycemia in Prader-Willi Syndrome
NCT01897363
University of Florida
CompletedAn Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
NCT01818921
Zafgen, Inc.Phase 2
CompletedEvaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Inf
NCT02205034
University Hospital, ToulousePhase 1 / Phase 2
CompletedPilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of H
NCT01863017
University of Kansas Medical CenterN/A
CompletedPWS European Blood Bank for Infants and Controls From 0 to 48 Months
NCT02529085
University Hospital, ToulouseN/A
TerminatedStudy of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks
NCT02810483
Assistance Publique - Hôpitaux de ParisPhase 3
UnknownAromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome
NCT01520467
Assistance Publique - Hôpitaux de ParisN/A
CompletedEffects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
NCT01444898
Children's Hospital Los AngelesN/A
TerminatedLiraglutide Use in Prader-Willi Syndrome
NCT01542242
Vancouver General HospitalPhase 4
CompletedBioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
NCT01401244
Novo Nordisk A/SPhase 1
CompletedTolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies
NCT01548521
University Hospital, ToulousePhase 1 / Phase 2
CompletedSleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
NCT02670694
Baylor College of Medicine
UnknownFamily-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study
NCT02058342
California State University, FullertonN/A
CompletedThe Intestinal Function in People With Prader-Willi Syndrome
NCT01523288
Aarhus University Hospital
CompletedComparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo
NCT01038570
University Hospital, ToulousePhase 2
RecruitingRegister of Patients With Prader-Willi Syndrome
NCT02829684
University Hospital, Toulouse
CompletedCortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls
NCT00932932
Children's Mercy Hospital Kansas City
CompletedIs There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?
NCT01298180
University Hospital, ToulousePhase 4
UnknownExploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome
NCT00808548
Taichung Veterans General Hospital
CompletedRetrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrom
NCT00705172
Novo Nordisk A/S
CompletedBehavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
NCT00742664
University of South FloridaPhase 1 / Phase 2
CompletedGut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
NCT00551343
Garvan Institute of Medical ResearchN/A
TerminatedEffect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome
NCT00603109
Weill Medical College of Cornell UniversityPhase 3
CompletedPlasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome
NCT01622751
Samsung Medical Center
CompletedPlasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Will
NCT01479322
Samsung Medical Center
TerminatedOctreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
NCT00399893
Duke UniversityN/A
CompletedCharacteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
NCT00375089
University of Florida
CompletedCorrelation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndr
NCT00474643
Samsung Medical Center
CompletedNordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syn
NCT00372125
Karolinska University HospitalN/A
CompletedGrowth Hormone Use in Adults With Prader-Willi Syndrome
NCT00444964
Children's Mercy Hospital Kansas CityPhase 3
CompletedCharacterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity
NCT01404624
Samsung Medical Center
TerminatedPrader-Willi Syndrome and Appetite
NCT00175305
University of British ColumbiaPhase 3
CompletedMacronutrient Regulation of Ghrelin and Peptide YY
NCT02464514
Duke UniversityN/A
CompletedTreatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome
NCT00065923
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)N/A
CompletedStudy of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
NCT00004351
National Institute of Neurological Disorders and Stroke (NINDS)
CompletedIncreased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
NCT00800852
Samsung Medical Center